Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

Quantum Genomics SA

Quantum Genomics SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)0.133
  • Today's Change0.003 / 2.47%
  • Shares traded6.34k
  • 1 Year change-17.29%
  • Beta0.6532
Data delayed at least 15 minutes, as of May 21 2024 12:18 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow Back to Overview

In millions of EUR
(except for per share items)
Fiscal data as of Dec 31 2022202220212020
OPERATIONS
Net income(25)(17)(12)
Depreciation/depletion--0.290.17
Non-Cash items0.4500.00
Cash taxes paid, supplemental------
Cash interest paid, supplemental------
Changes in working capital9.51(0.59)(0.59)
Total cash from operations(15)(17)(12)
INVESTING
Capital expenditures(0.03)(0.05)(0.41)
Other investing and cash flow items, total(0.12)0.02(0.17)
Total cash from investing(0.15)(0.03)(0.58)
FINANCING
Financing cash flow items----0.00
Total cash dividends paid------
Issuance (retirement) of stock, net170.8529
Issuance (retirement) of debt, net0.032.440.03
Total cash from financing173.2929
NET CHANGE IN CASH
Foreign exchange effects------
Net change in cash2.09(14)16
Net cash-begin balance/reserved for future use142711
Net cash-end balance/reserved for future use161427
SUPPLEMENTAL INCOME
Depreciation, supplemental--0.290.17
Cash interest paid, supplemental------
Cash taxes paid, supplemental------
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.